Progress, Potential, and Possibilities Podcast / Show · 2026-07-06 · 55 min
Send us Fan Mail For decades we've treated autoimmune diseases by suppressing the immune system - but what if we've been approaching the problem all wrong? What if, instead of lifelong immunosuppression, we could selectively eliminate the immune cells causing disease and allow the immune system to rebuild itself? Today we're exploring one of the hottest areas in biotechnology: T-cell engagers and the possibility of an "immune reset." Dr. Jeffrey Jones, MD, MPH is Chief Medical Officer of Cullinan Therapeutics ( ) and one of the leaders helping bring the power of T-cell engager therapies beyond cancer and into autoimmune disease. With more than two decades of experience spanning academia and industry, Dr. Jones has been at the forefront of clinical development in hematology, oncology, and immunology. Prior to joining Cullinan, Dr. Jones served as Vice President of Global Drug Development at Bristol Myers Squibb, leading programs in lymphoma and myeloid diseases and helping guide the lifecycle strategy for Reblozyl®. Earlier, he held leadership positions at Celgene, where he developed clinical strategies across lymphoma and chronic lymphocytic leukemia portfolios.
Other episodes covering the same guests and topics, from across The B2B Podcast Index.
Building the Internet of Medicine: How AI Could Transform Children's Healthcare | Dr. Timothy Chou - Founder, Pediatric Moonshot92 / 100The Blood Test That Could Change Cancer Treatment Forever | Eric Matthews - General Manager, Biopharma, Natera65 / 100How Female Biology Shapes Skin Disease Across a Lifetime | Dr. Doral Fredericks, PharmD, MBA - Vice President and Head of Global Medical Affairs and Outcomes Research, Organon56 / 10055 Years Without a Diagnosis | Can AI Solve The Undiagnosed Condition Blind Spot? | Haresh Patel - Founder and CEO, Sanare Health AI70 / 100How Regenerative Medicine Is Reinventing Breast Reconstruction | Dr. Claudia Chavez-Munoz, MD, PhD - Chief Scientific Officer and Co-Founder - Conexeu Sciences
